Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2025-12-25 @ 9:43 PM
Study NCT ID:
NCT01538251
Status:
TERMINATED
Last Update Posted:
2016-11-07
First Post:
2012-02-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003093', 'term': 'Colitis, Ulcerative'}], 'ancestors': [{'id': 'D003092', 'term': 'Colitis'}, {'id': 'D005759', 'term': 'Gastroenteritis'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D015212', 'term': 'Inflammatory Bowel Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 147}}, 'statusModule': {'whyStopped': 'Evidence of very low probability to success. No safety issues.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2012-04'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-11', 'completionDateStruct': {'date': '2013-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-11-04', 'studyFirstSubmitDate': '2012-02-20', 'studyFirstSubmitQcDate': '2012-02-23', 'lastUpdatePostDateStruct': {'date': '2016-11-07', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-02-24', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of clinical/endoscopic remissions', 'timeFrame': 'End of treatment (week 8)', 'description': 'Remission will be defined according with the overall modified Mayo score (Disease Activity Index). A score ≤ 2 with rectal bleeding sub-score = 0 and no other individual sub-score \\>1 will be considered necessary to classify the patient in remission state.'}], 'secondaryOutcomes': [{'measure': 'Change from baseline in Rectal bleeding evaluation', 'timeFrame': 'At week 2, 6 and 8 of treatment and after 4 week follow-up', 'description': 'Evaluation will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).'}, {'measure': 'Change from baseline in stool frequency evaluation', 'timeFrame': 'At week 2, 6 and 8 of treatment and after 4 week follow-up', 'description': 'Evaluations will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).'}, {'measure': 'Histological response to the treatment', 'timeFrame': 'End of treatment (week 8)', 'description': 'Evaluated as an improvement of the histological index of at least 1 point'}, {'measure': 'Change from baseline in C-reactive protein (CRP) and Fibrinogen', 'timeFrame': 'End of the treatment (week 8) and after 4 week follow-up'}, {'measure': 'Improvement of patients quality of life', 'timeFrame': 'End of treatment period (week8) and after 4 week follow-up', 'description': "A validated specific questionnaire, the SIBDQ by McMaster university will be administered to evaluate changes in patients' quality of life"}, {'measure': 'Haematology', 'timeFrame': 'Baseline and end of treatment (week8)'}, {'measure': 'Electrocardiogram', 'timeFrame': 'At baseline and at the end of treatment period (week8)'}, {'measure': 'Adverse Events collection', 'timeFrame': '8 weeks'}, {'measure': 'Serum Chemistry', 'timeFrame': 'At baseline and at the end of treatment period (week8)'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['ulcerative colitis', 'propionyl-l-carnitine'], 'conditions': ['Ulcerative Colitis']}, 'descriptionModule': {'briefSummary': 'The aim of the trial is to test safety, tolerability and efficacy of Propionyl-L-carnitine modified release tablets 1g/die in reducing the symptoms of the disease with respect to the proportion of patients with disease remission at the end of the 8 weeks of treatment. It will also aim to investigate capability of the treatment in the maintenance of remission after four weeks of treatment interruption; histological changes will be also evaluated and finally, improvement in the overall quality of life as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)will be investigated.', 'detailedDescription': 'Although it seems clear that an abnormal function of the colonic epithelium is the central problem causing inflammation and the unusual immunological response to the normal gut flora in inflammatory bowel disease (IBD), the actual causes of these dysfunctions are still unknown.\n\nShort Chain Fatty Acids (SCFA) are the main fuel of the colonic epithelium, and are normally produced by the bacterial flora by fermentation of the complex carbohydrates forming non soluble fibers usually introduced with everyday diet. Butyrate alone contributes 70% of the normal colonocyte energy.\n\nStudies done using animal models and colonic mucosa biopsies from patients suffering form ulcerative colitis (UC) have consistently shown that a metabolic change occurs in diseased colonic mucosa, with an impairment of butyrate oxidation (and of beta-oxidation) and an energy shortage that is only incompletely compensated by oxidation of glucose and other substrates such as glutamine.\n\nIt is also well known that matrix metalloproteases production is highly increased in IBD and that serum transglutaminase activity is significantly reduced in patients with IBD.\n\nTransglutaminases are enzymes contributing to the crosslinking of matrix proteins and the reduction seen in patients affected by IBD correlates well with the endoscopic and histopathologic grading in UC, meaning that part of the circulating enzyme is sequestered in the injured colonic tissue in the effort to re-build the extracellular matrix during the healing process.\n\nPropionyl-L-carnitine Hydrochloride (PLC) is a molecule that has already been shown to reduce membrane lipid peroxidation in endothelial cells from bovine aorta and coronary vessels, to reduce the effects of hypoxia in coronary endothelial cells, and to play a role in the cardiac metabolic abnormalities that contribute to the mechanical dysfunctions leading to heart failure.\n\nGiven these properties of Propionyl-L-carnitine Hydrochloride (ST 261) and given the peroxidative damage suffered by colonocytes in UC together with their metabolic impairment, the use of this molecule for the treatment of UC seemed to be appropriate and sound, in particular as a carrier of a propionate moiety that, once transformed into succinate, enters the Kreb cycle, acting as an extra burst fuel improving the balance of energy production inside tissues.\n\nPrevious clinical experience has shown that PLC promoted complete or nearly complete regression of cutaneous trophic ulcers in a large number of vasculopathic patients refractory to all other therapies.\n\nAs far as the UC pathology is concerned, the effects of ST 261, given orally or intrarectally, were investigated at different dosages, in preclinical experimentation, either after a single trinitrobenzene sulphonic acid (TNBS) administration (acute colitis) or after repeated TNBS administrations (reactivated colitis). The results showed a reduction in the damaged colon area both in acute model and reactivated colitis, even if the beneficial effect of restoration of TNBS-induced alterations of tissue morphology is more evident in the reactivated colitis model, particularly after oral administration.\n\nBased on the above-described results a development plan in humans started to investigate the activity of PLC in the treatment of ulcerative colitis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Have read the Information for the Patient and signed the Informed Consent Form.\n* Diagnosis of active ulcerative colitis since at least 4 weeks as confirmed endoscopically and histologically.\n* Disease Activity Index comprised between 3 and 6, inclusive (mild ulcerative colitis), with rectal bleeding sub-score of at least 1.\n* Stable background oral aminosalicylates (mesalazine, balsalazide, olsalazine) or sulfasalazine standard therapy for greater than or equal to 4 weeks prior to screening assessments.\n* If female, not pregnant or nursing. For women of childbearing potential, willingness to avoid a pregnancy during the treatment period and for at least 4 weeks from the last dose of drug and utilization of an efficient method of birth control for the entire duration of the trial and until the first menses after a 30-day period after the last dose of trial medication.\n\nExclusion Criteria:\n\n* Crohn's disease and indeterminate colitis.\n* Current or previous (in the last 10 days preceding the screening) use of systemic corticosteroids.\n* Use of systemic antibiotics in the last 10 days preceding the screening.\n* Use of systemic Nonsteroidal anti-inflammatory drugs on a repeat basis in the last 10 days preceding the screening.\n* Use of probiotics started within 10 days preceding the screening. A stable regimen from at least 10 days prior to screening is allowed but the patient must be willing to continue up to the end of the study.\n* Use of immunosuppressants or biological agents within the last 6 weeks preceding the screening.\n* Treatment with L-carnitine or its esters derivatives within the last 3 months.\n* Stool culture positive for enteric pathogens (eg, Shigella, Salmonella, Yersinia, Campylobacter) or toxins (C.difficile).\n* Significantly impaired liver, renal, pulmonary or cardiovascular function as assessed by the investigator.\n* History of colon resection.\n* Diverticulitis, symptomatic diverticulosis.\n* Active peptic ulcer disease.\n* Proctitis (extent of inflammation \\<15 cm from the anus).\n* Bleeding disorders\n* Rectal therapy with any therapeutic enemas or suppositories with the exception of those required for endoscopy during the 10 days preceding the screening.\n* Active or chronic infection(s) or malignancies.\n* Known hypersensitivity to the active ingredient and excipients of the study drug."}, 'identificationModule': {'nctId': 'NCT01538251', 'briefTitle': 'Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis', 'organization': {'class': 'INDUSTRY', 'fullName': 'sigma-tau i.f.r. S.p.A.'}, 'officialTitle': 'Randomized Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis Under Oral Stable Treatment', 'orgStudyIdInfo': {'id': 'ST261DM11005'}, 'secondaryIdInfos': [{'id': '2011-004765-32', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Propionyl-L-carnitine', 'description': 'modified release tablets 500 mg', 'interventionNames': ['Drug: Propionyl-L-Carnitine']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Modified release tablet 500 mg', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Propionyl-L-Carnitine', 'type': 'DRUG', 'description': 'Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.', 'armGroupLabels': ['Propionyl-L-carnitine']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '2820', 'city': 'Bonheiden', 'state': 'Antwerpen', 'country': 'Belgium', 'facility': 'Imelda Ziekenhuis', 'geoPoint': {'lat': 51.02261, 'lon': 4.54714}}, {'zip': '3000', 'city': 'Leuven', 'state': 'Flemish Brabant', 'country': 'Belgium', 'facility': 'Universitaire Ziekenhuis Gasthuisberg', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '9000', 'city': 'Ghent', 'state': 'Oost-vlaanderen', 'country': 'Belgium', 'facility': 'Universitair Ziekenhuis Gent', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'zip': '8800', 'city': 'Roeselare', 'state': 'West-vlaanderen', 'country': 'Belgium', 'facility': 'H. Hartziekenhuis Roeselare-Menen vzw', 'geoPoint': {'lat': 50.94653, 'lon': 3.12269}}, {'zip': '370 01', 'city': 'České Budějovice', 'country': 'Czechia', 'facility': 'Derma Plus s.r.o.', 'geoPoint': {'lat': 48.97447, 'lon': 14.47434}}, {'zip': '500 12', 'city': 'Hradec Králové', 'country': 'Czechia', 'facility': 'Hepato-Gastroenterology HK s.r.o.', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'zip': '775 20', 'city': 'Olomouc', 'country': 'Czechia', 'facility': 'Fakultní nemocnice Olomouc', 'geoPoint': {'lat': 49.59552, 'lon': 17.25175}}, {'zip': '100 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'G.E.P. Clinic s.r.o.', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '118 33', 'city': 'Prague', 'country': 'Czechia', 'facility': 'MONSE s.r.o', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '15006', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Fakultní Nemocnice v Motole', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '140 59', 'city': 'Praha 4 - Krc', 'country': 'Czechia', 'facility': 'Fakultní Thomayerova nemocnice s poliklinikou'}, {'zip': '390 03', 'city': 'Tábor', 'country': 'Czechia', 'facility': 'Nemocnice Tábor, a.s.', 'geoPoint': {'lat': 49.41441, 'lon': 14.6578}}, {'zip': '562 18', 'city': 'Ústí nad Orlicí', 'country': 'Czechia', 'facility': 'Orlickoústecká Nemocnice a.s', 'geoPoint': {'lat': 49.97387, 'lon': 16.39361}}, {'zip': '84100', 'city': 'Beersheba', 'country': 'Israel', 'facility': 'Soroka University Medical Center', 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}}, {'zip': '91031', 'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Shaare Zedek Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Hadassah Medical Organization, Ein Kerem', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '44281', 'city': 'Kfar Saba', 'country': 'Israel', 'facility': 'Meir Medical Center', 'geoPoint': {'lat': 32.175, 'lon': 34.90694}}, {'zip': '49100', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Rabin Medical Center', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '76100', 'city': 'Rehovot', 'country': 'Israel', 'facility': 'Kaplan Medical Center', 'geoPoint': {'lat': 31.89421, 'lon': 34.81199}}, {'zip': '64239', 'city': 'Tel Aviv', 'country': 'Israel', 'facility': 'Tel Aviv Souraski Medical Center', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '70300', 'city': 'Ẕerifin', 'country': 'Israel', 'facility': 'Assaf Harofeh Medical Centre', 'geoPoint': {'lat': 31.95731, 'lon': 34.84852}}, {'zip': '47100', 'city': 'Forlì', 'state': 'Forli-cesena', 'country': 'Italy', 'facility': 'Ospedale "G.B.Morgagni - L. Pierantoni"', 'geoPoint': {'lat': 44.22177, 'lon': 12.04144}}, {'zip': '20089', 'city': 'Rozzano', 'state': 'Milano', 'country': 'Italy', 'facility': 'Istituto Clinico Humanitas', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '20157', 'city': 'Milan', 'country': 'Italy', 'facility': 'Ospedale Luigi Sacco - Az. Osp. Dept. of Gastroenterology', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '80131', 'city': 'Napoli', 'country': 'Italy', 'facility': 'Policlinico Universitario Federico II', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '27100', 'city': 'Pavia', 'country': 'Italy', 'facility': 'IRCSS Policlinico San Matteo', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'zip': '00152', 'city': 'Roma', 'country': 'Italy', 'facility': 'Azienda Ospedaliera S. Camillo Forlanini, Roma', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '00168', 'city': 'Roma', 'country': 'Italy', 'facility': 'Policlinico Universitario Agostino Gemelli', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '1091 AC', 'city': 'Amsterdam', 'state': 'North Holland', 'country': 'Netherlands', 'facility': 'Onze Lieve Vrouwe Gasthuis', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '2333 ZA', 'city': 'Leiden', 'state': 'South Holland', 'country': 'Netherlands', 'facility': 'Leids Universitair Medisch Centrum', 'geoPoint': {'lat': 52.15833, 'lon': 4.49306}}, {'zip': '3584 CX', 'city': 'Utrecht', 'state': 'Utrecht', 'country': 'Netherlands', 'facility': 'UMC Utrecht', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}, {'zip': '540461', 'city': 'Târgu Mureş', 'state': 'Mureș County', 'country': 'Romania', 'facility': 'CMI de Gastroenterologie Dobru Daniela', 'geoPoint': {'lat': 46.54245, 'lon': 24.55747}}, {'zip': '500283', 'city': 'Brasov', 'country': 'Romania', 'facility': 'Neomed Research', 'geoPoint': {'lat': 45.64861, 'lon': 25.60613}}, {'zip': '011025', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Centrul Medical Sana', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '021978', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Endocenter Medicina Integrativa SRL', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '700506', 'city': 'Iași', 'country': 'Romania', 'facility': 'Gastromedica SRL', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'zip': '550245', 'city': 'Sibiu', 'country': 'Romania', 'facility': 'Spitalul Clinic Judetean De Urgenta Sibiu', 'geoPoint': {'lat': 45.8, 'lon': 24.15}}, {'zip': '300002', 'city': 'Timișoara', 'country': 'Romania', 'facility': 'Policlinic Algomed SRL', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'zip': '123423', 'city': 'Moscow', 'country': 'Russia', 'facility': 'State Scientific Centre of Coloproctology', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '630091', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'State Educational Institution of Higher Professional Education Novosibirsk State Medical University', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '630117', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'State Research Institute of Physiology of Siberian Branch of Russian Academy of Medical Sciences', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '344022', 'city': 'Rostov-on-Don', 'country': 'Russia', 'facility': 'GOU VPO Rostov State Medical University', 'geoPoint': {'lat': 47.21997, 'lon': 39.70769}}, {'zip': '193015', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Saint Petersburg GUZ City Policlinic 38', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '193124', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Regional Military Clinical Hospital ¿ 442 named after Z.P. Solovyov of Ministry of Defence of Russia', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '195067', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Saint-Petersburg Medical Academy', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '196247', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Saint-Petersburg State Institution of Health Protection City Hospital # 26', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '197110', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Krestovsky Medical Institute', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '410053', 'city': 'Saratov', 'country': 'Russia', 'facility': 'Saratov City Hospital #2', 'geoPoint': {'lat': 51.54048, 'lon': 45.9901}}, {'zip': '355017', 'city': 'Stavropol', 'country': 'Russia', 'facility': 'State Educational Institution of Higher Professional Education "Stavropol State Medical Academy"', 'geoPoint': {'lat': 45.03442, 'lon': 41.9642}}, {'zip': '150010', 'city': 'Yaroslavl', 'country': 'Russia', 'facility': 'Clinical Hospital #2', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'zip': '974 01', 'city': 'Banská Bystrica', 'country': 'Slovakia', 'facility': 'NovaMed spol. s.r.o.', 'geoPoint': {'lat': 48.73947, 'lon': 19.14932}}, {'zip': '813 69', 'city': 'Bratislava', 'country': 'Slovakia', 'facility': 'UNB Nemocnica Staré Mesto', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '82101', 'city': 'Bratislava', 'country': 'Slovakia', 'facility': 'ABAWI spol.s.r.o.', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '831 04', 'city': 'Bratislava', 'country': 'Slovakia', 'facility': 'Lama Medical Care s.r.o., Gastroentero-hepatologicke centrum Thalion', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '851 01', 'city': 'Bratislava', 'country': 'Slovakia', 'facility': 'Neštátna Gastroenterologická Ambulancia', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '950 01', 'city': 'Nitra', 'country': 'Slovakia', 'facility': 'KM Management sro', 'geoPoint': {'lat': 48.30763, 'lon': 18.08453}}, {'zip': '08001', 'city': 'Prešov', 'country': 'Slovakia', 'facility': 'Gastro I.s.r.o.', 'geoPoint': {'lat': 48.99923, 'lon': 21.2355}}, {'zip': '91701', 'city': 'Trnava', 'country': 'Slovakia', 'facility': 'GEA s.r.o Gastroenterologicka ambulancia', 'geoPoint': {'lat': 48.37773, 'lon': 17.58603}}], 'overallOfficials': [{'name': 'Sandro Ardizzone, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Head of Inflammatory Bowel Diseases Unit Hospital "Luigi Sacco" Milan - ITALY'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'sigma-tau i.f.r. S.p.A.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}